These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 12812377)

  • 1. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in the development of anticoagulant and antithrombotic drugs.
    Fareed J; Hoppensteadt D; Walenga JM; Bick RL
    Med Clin North Am; 1994 May; 78(3):713-31. PubMed ID: 8170266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of different anticoagulant agents on fibrinopeptide a generation.
    Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Garcia DA; Baglin TP; Weitz JI; Samama MM
    Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
    Wong GC; Giugliano RP; Antman EM
    JAMA; 2003 Jan; 289(3):331-42. PubMed ID: 12525234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging anticoagulant and thrombolytic drugs.
    Iqbal O; Aziz S; Hoppensteadt DA; Ahmad S; Walenga JM; Bakhos M; Fareed J
    Expert Opin Emerg Drugs; 2001 Apr; 6(1):111-35. PubMed ID: 15989500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status on new anticoagulant and antithrombotic drugs and devices.
    Walenga JM; Fareed J
    Curr Opin Pulm Med; 1997 Jul; 3(4):291-302. PubMed ID: 9262116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of anticoagulation.
    Hoppensteadt DA; Jeske W; Walenga J; Fareed J
    Semin Respir Crit Care Med; 2008 Feb; 29(1):90-9. PubMed ID: 18302091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventional cardiovascular pharmacotherapy: current issues.
    Rebeiz AG; Adams J; Harrington RA
    Am J Cardiovasc Drugs; 2005; 5(2):93-102. PubMed ID: 15725040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin agents: the new class of anticoagulant and antithrombotic drugs.
    Fareed J; Lewis BE; Callas DD; Hoppensteadt DA; Walenga JM; Bick RL
    Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S45-55. PubMed ID: 10726036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.